RetaMaps

Ross Bridge Medical Center

Ross Bridge Medical Center · 3635 Market Street · Hoover, AL 35226

4.8· 1,029 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

Ross Bridge Medical Center is a primary care clinic in Hoover, Alabama that, per its website, also provides pediatrics, psychiatry, women's health and aesthetic services. The site highlights same-day appointments, telephone and video visits, on-site lab testing and X-rays, and after-hours on-call care, and its listing includes weight-loss care, hormone care and IV therapy. On Google it holds a 4.8-star rating across 1,029 reviews dating back to 2019, with 68 posted in the past year; reviewers most often mention the staff and a caring approach, and 7 mention scheduling.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.8
Google rating · 1,029 reviews
68
reviews in the past year (avg ★ 4.7)
1
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-26. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.8 across 1,029 Google reviews. Of the 100 reviews we analyzed, 91 (91%) are positive (4–5★) and 7 (7%) are negative (1–2★).

What patients like

  • Friendly, helpful staff42 reviews
  • Feeling listened to22 reviews
  • Knowledgeable, professional providers20 reviews
  • Easy scheduling and communication5 reviews

Common complaints

  • Staff or front-desk issues2 of 7 negative
  • Scheduling or communication problems2 of 7 negative
5★
87
4★
4
3★
2
2★
1
1★
6

Most recent Google reviews

Aerial T.★★★★★2026-09-26

Very family oriented, and fast service

Laura R.★★★★★2026-09-25

Wonderful personnel: front desk, nurses, doctors!!

Suvas b.★★★★★2026-09-25

Everything is exceptional.

Andy W.★★★★★2026-09-23

The ladies at the front desk and nurses in the back were all very professional and welcoming. And the doctor was very polite and listened to everything I had to say.. I will be recommending him to my friends and family! Thank you Dr.

Karen C.★★★★★2026-09-21

My brother was new to the area and needed prescriptions filled. I am his caretaker and needed to get him in asap. The front desk requested an emergency appointment due to my brother having had a stroke in June. Dr Devani was very compassionate with my brother and assured him he would follow his recovery needs. It was a very good visit. We had to wait a little extra time but it was very necessary we get him seen.

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Hoover

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs